Is Airsupra in shortage in 2026? Get the latest update on availability, pricing, and what patients can do if they can't find this rescue inhaler.
If you're having trouble finding Airsupra at your pharmacy, you might be wondering: is there a shortage? The short answer is no — Airsupra is not on the FDA's official drug shortage list as of March 2026. AstraZeneca continues to manufacture and distribute the medication.
But that doesn't mean it's easy to find. Many patients report calling multiple pharmacies only to hear "we don't carry that" or "it's not in stock." The reasons have less to do with manufacturing and more to do with the unique challenges facing newer, expensive brand-name medications.
Let's break down what's actually going on and what you can do about it.
Even though Airsupra isn't formally in shortage, several factors make it harder to find than your typical rescue inhaler:
Airsupra's list price is $503.93 per inhaler as of January 2026. For comparison, a generic Albuterol inhaler costs $25 to $90. This price gap means pharmacies are cautious about stocking an expensive product that may sit on their shelves. If patients can't afford it or their insurance doesn't cover it, the pharmacy ends up with an expensive product that doesn't sell.
There is no generic version of Airsupra as of 2026. When a medication is available only as a brand-name product, inventory is controlled by a single manufacturer, and pharmacies may be less inclined to stock it compared to medications with multiple generic options.
While most commercial insurance plans cover Airsupra, many require prior authorization or step therapy before they'll pay for it. This means your doctor may need to submit paperwork proving you need Airsupra instead of a standard Albuterol inhaler. Some Medicare Part D plans don't cover it at all. These barriers reduce the number of patients who can easily fill the prescription, which in turn reduces pharmacy demand.
Airsupra was approved in January 2023 — it's still relatively new in the market. Not all physicians are prescribing it yet, and not all pharmacies have added it to their regular inventory. As awareness grows and more prescriptions come through, availability should improve.
Here's a quick breakdown of what you might pay:
For a complete guide to reducing your cost, see our article on how to save money on Airsupra in 2026.
Several developments in 2025 and 2026 have improved the landscape for Airsupra patients:
In September 2025, AstraZeneca updated Airsupra's prescribing information to include data showing a statistically significant reduction in severe exacerbations in patients with mild asthma compared to Albuterol alone. This strengthened the clinical case for Airsupra and may make it easier for doctors to get prior authorization approved.
More insurance plans have added Airsupra to their formularies since its launch. While coverage isn't universal, the trend is moving in the right direction. The SUPRA Savings Card continues to help bridge the gap for commercially insured patients.
Medical guidelines increasingly support the use of ICS-containing rescue inhalers (like Airsupra) and MART therapy as preferred strategies for asthma management. This is driving more prescribers to consider Airsupra and similar approaches, which should increase demand and pharmacy stocking over time.
Here are the most effective strategies for finding Airsupra right now:
For more detailed strategies, read our full guide on how to find Airsupra in stock near you.
If you need a rescue inhaler right now and can't get Airsupra today, talk to your doctor about a temporary alternative. A standard Albuterol inhaler is widely available and affordable, and your doctor may want you to use it alongside a daily inhaled corticosteroid controller to get some of the anti-inflammatory benefit you'd get from Airsupra.
Another option is Symbicort (or its generic, Breyna) used as MART therapy — a single inhaler for both daily control and rescue. Learn more about your options in our article on alternatives to Airsupra.
Airsupra is not in a formal shortage in 2026, but it's not always easy to find. The challenges come from its high price, brand-name-only status, and inconsistent insurance coverage — not from a manufacturing problem. The situation is improving as more insurers cover it and more pharmacists become familiar with it.
In the meantime, use tools like Medfinder to locate it, explore savings programs to make it affordable, and always have a backup rescue inhaler plan in place. Your asthma shouldn't have to wait for the system to catch up.
For a full overview of Airsupra, see what is Airsupra: uses, dosage, and what you need to know.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
